Actualités MyMD Pharmaceuticals Inc - MYMD | Actions NASDAQ

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Current Report Filing (8-k)

0001321834 false 0001321834 2023-06-09 2023-06-09 iso4217:USD xbrli:shares...

Current Report Filing (8-k)

0001321834 false 0001321834 2023-04-12 2023-04-12 iso4217:USD xbrli:shares...

MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

- Currently, there are no FDA-approved treatments for sarcopenia/frailty - - MyMD is only 3 patients away from dosing its final patient in its...

MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis

Preclinical results showed MYMD-1® significantly reduced histopathological changes and the severity of standard arthritis clinical trial measures...

Proxy Statement (definitive) (def 14a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A...

Current Report Filing (8-k)

0001321834 false 0001321834 2023-03-08 2023-03-08 iso4217:USD xbrli:shares...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

MyMD Pharmaceuticals Inc (MYMD)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

MYMD Actualités

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Current Report Filing (8-k)

Current Report Filing (8-k)

MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

Statement of Changes in Beneficial Ownership (4)

Current Report Filing (8-k)

Annual Report (10-k)

Current Report Filing (8-k)

Current Report Filing (8-k)

MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis

Proxy Statement (definitive) (def 14a)

Current Report Filing (8-k)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

BLACK FRIDAY

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

MyMD Pharmaceuticals Inc (MYMD) Actualités

MyMD Pharmaceuticals Inc (MYMD)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

MYMD Actualités

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Current Report Filing (8-k)

Current Report Filing (8-k)

MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

Statement of Changes in Beneficial Ownership (4)

Current Report Filing (8-k)

Annual Report (10-k)

Current Report Filing (8-k)

Current Report Filing (8-k)

MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis

Proxy Statement (definitive) (def 14a)

Current Report Filing (8-k)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

BLACK FRIDAY

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres